Gulf Pharmaceutical Industries

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: AEG000201018
AED
1.21
0.02 (1.68%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Net Sales of 12.96%, the company declared Very Positive results in Jun 25

  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at AED 145.7 MM
  • ROCE(HY) Highest at 6.2%
  • INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
2

With ROE of 2.04%, it has a expensive valuation with a 2.00 Price to Book Value

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

AED 1,363 Million (Micro Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.01

stock-summary
Return on Equity

6.98%

stock-summary
Price to Book

1.41

Revenue and Profits:
Net Sales:
348 Million
(Quarterly Results - Jun 2025)
Net Profit:
17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-15.38%
0%
-15.38%
1 Year
-22.44%
0%
-22.44%
2 Years
17.48%
0%
17.48%
3 Years
8.04%
0%
8.04%
4 Years
-29.65%
0%
-29.65%
5 Years
-26.67%
0%
-26.67%

Gulf Pharmaceutical Industries for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
12.42%
EBIT Growth (5y)
18.91%
EBIT to Interest (avg)
-2.30
Debt to EBITDA (avg)
73.60
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.80
Tax Ratio
10.72%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.26%
ROE (avg)
0.76%

Valuation key factors

Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.61
EV to EBIT
22.25
EV to EBITDA
11.29
EV to Capital Employed
1.60
EV to Sales
1.36
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
7.20%
ROE (Latest)
5.76%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.09% vs 2,820.33% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -22.12% vs -7.26% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "348.10",
          "val2": "359.20",
          "chgp": "-3.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.50",
          "val2": "47.80",
          "chgp": "-17.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "15.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.90",
          "val2": "21.70",
          "chgp": "-22.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "68.70%",
          "val2": "89.90%",
          "chgp": "-2.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.74% vs -20.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 121.48% vs -184.27% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,312.50",
          "val2": "1,277.50",
          "chgp": "2.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.10",
          "val2": "-33.20",
          "chgp": "290.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "62.20",
          "val2": "56.30",
          "chgp": "10.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.30",
          "val2": "-75.90",
          "chgp": "121.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "48.10%",
          "val2": "-26.00%",
          "chgp": "7.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
348.10
359.20
-3.09%
Operating Profit (PBDIT) excl Other Income
39.50
47.80
-17.36%
Interest
7.60
15.20
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
16.90
21.70
-22.12%
Operating Profit Margin (Excl OI)
68.70%
89.90%
-2.12%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -3.09% vs 2,820.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -22.12% vs -7.26% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1,312.50
1,277.50
2.74%
Operating Profit (PBDIT) excl Other Income
63.10
-33.20
290.06%
Interest
62.20
56.30
10.48%
Exceptional Items
0.00
0.00
Consolidate Net Profit
16.30
-75.90
121.48%
Operating Profit Margin (Excl OI)
48.10%
-26.00%
7.41%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 2.74% vs -20.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 121.48% vs -184.27% in Dec 2023

stock-summaryCompany CV
About Gulf Pharmaceutical Industries stock-summary
stock-summary
Gulf Pharmaceutical Industries
Pharmaceuticals & Biotechnology
Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Company’s subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.
Company Coordinates stock-summary
Company Details
Digdaga Airport Road, P.O.Box 997 RAS AL KHAIMAH CITY None : None
stock-summary
Tel: 971 7 2461461971 7 2045273
stock-summary
Registrar Details